GSBR-1290

About Structure Therapeutics

Structure Therapeutics is pioneering the development of next-generation oral small molecule medicines targeting G protein-coupled receptors (GPCRs), a historically challenging but highly validated class of drug targets. The company's lead asset, GSBR-1290, is a highly selective oral GLP-1 receptor agonist in Phase 2 development for obesity and type 2 diabetes, aiming to compete with injectable GLP-1 therapies. With a strong pipeline of preclinical candidates for other cardiometabolic and pulmonary conditions, Structure is positioned at the forefront of the oral incretin market. The company's strategy is built on its integrated computational and experimental platform to design differentiated therapeutics with improved patient convenience and adherence.

About Structure Therapeutics

Structure Therapeutics is pioneering the development of next-generation oral small molecule medicines targeting G protein-coupled receptors (GPCRs), a historically challenging but highly validated class of drug targets. The company's lead asset, GSBR-1290, is a highly selective oral GLP-1 receptor agonist in Phase 2 development for obesity and type 2 diabetes, aiming to compete with injectable GLP-1 therapies. With a strong pipeline of preclinical candidates for other cardiometabolic and pulmonary conditions, Structure is positioned at the forefront of the oral incretin market. The company's strategy is built on its integrated computational and experimental platform to design differentiated therapeutics with improved patient convenience and adherence.

Therapeutic Areas

Other Obesity Drugs